Triple biologic therapy for refractory Crohn’s disease
Triple biologic therapy remains experimental and should be approached with caution, pending more robust evidence. Larger and translational studies are needed to better identify patients who may benefit, define optimal combinations, and clarify long-term safety of these combinations.
Authors
- Sophie Vieujean (ORCID: https://orcid.org/0000-0002-1859-7146)
- Laurent Peyrin-Biroulet
Institutions
- Centre Hospitalier Universitaire de Liège (BE)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1093/ecco-jcc/jjaf067
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82